SAEs · NSTI
Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).
1 finding from 1 review
Survival time · NSTI
1 finding from 1 review
Assessment of long‐term morbidity · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · NSTI
It is very uncertain whether moxifloxacin changes serious adverse events (SAE) compared with amoxicillin‐clavulanate (very low certainty).
1 finding from 1 review
Survival time · NSTI
1 finding from 1 review
Assessment of long‐term morbidity · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · NSTI
It is very uncertain whether AB103 changes mortality compared with placebo (very low certainty).
1 finding from 1 review
SAEs · NSTI
It is very uncertain whether AB103 changes serious adverse events (SAE) compared with placebo (very low certainty).
1 finding from 1 review
Survival time · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Assessment of long‐term morbidity · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · NSTI
Intravenous immunoglobulin showed no clear difference in mortality compared with placebo (low certainty).
1 finding from 1 review
Clearing or excellent improvement · people with discoid lupus erythematosus
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Clearing or excellent improvement · people with discoid lupus erythematosus
1 finding from 1 review
At least 50% reduction in erythema · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life measure · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Relapse · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Clearing or excellent improvement · people with discoid lupus erythematosus
1 finding from 1 review
At least 50% reduction in erythema · people with discoid lupus erythematosus
1 finding from 1 review